Executive Summary
Natural Beauty Bio-Technology Limited, an investment holding company, manufactures and sells skin care, beauty, aroma-therapeutic, and health supplements and make-up products under the Natural Beauty brand in the People’s Republic of China, Taiwan, and internationally. More Details
Risk Analysis
Snowflake Analysis
Excellent balance sheet with weak fundamentals.
Share Price & News
How has Natural Beauty Bio-Technology's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 157 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 157's weekly volatility (7%) has been stable over the past year.
Market Performance
7 Day Return
-5.6%
157
-3.7%
HK Personal Products
-4.3%
HK Market
1 Year Return
n/a
157
-3.0%
HK Personal Products
8.2%
HK Market
Return vs Industry: Insufficient data to determine how 157 performed against the Hong Kong Personal Products industry.
Return vs Market: Insufficient data to determine how 157 performed against the Hong Kong Market.
Shareholder returns
| 157 | Industry | Market | |
|---|---|---|---|
| 7 Day | -5.6% | -3.7% | -4.3% |
| 30 Day | -4.3% | -8.0% | -9.4% |
| 90 Day | -2.9% | 2.0% | -9.8% |
| 1 Year | n/a | 1.4%-3.0% | 12.0%8.2% |
| 3 Year | -14.5%-16.3% | 0.3%-10.2% | 10.0%-2.3% |
| 5 Year | 18.2%-8.2% | -0.8%-16.5% | 38.9%14.3% |
Long-Term Price Volatility Vs. Market
How volatile is Natural Beauty Bio-Technology's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall St
Is Natural Beauty Bio-Technology Limited (HKG:157) Popular Amongst Insiders?1 month ago | Simply Wall St
Natural Beauty Bio-Technology (HKG:157) Has Some Difficulty Using Its Capital EffectivelyValuation
Is Natural Beauty Bio-Technology undervalued compared to its fair value and its price relative to the market?
172.95x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 157 (HK$0.67) is trading above our estimate of fair value (HK$0.03)
Significantly Below Fair Value: 157 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 157 is poor value based on its PE Ratio (172.9x) compared to the Hong Kong Personal Products industry average (6.8x).
PE vs Market: 157 is poor value based on its PE Ratio (172.9x) compared to the Hong Kong market (10.6x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 157's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 157 is overvalued based on its PB Ratio (2.2x) compared to the HK Personal Products industry average (0.7x).
Future Growth
How is Natural Beauty Bio-Technology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
18.1%
Forecasted Household industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Natural Beauty Bio-Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Natural Beauty Bio-Technology performed over the past 5 years?
-47.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 157 has a large one-off loss of HK$2.7M impacting its December 31 2020 financial results.
Growing Profit Margin: 157's current net profit margins (1.9%) are lower than last year (5%).
Past Earnings Growth Analysis
Earnings Trend: 157's earnings have declined by 47.8% per year over the past 5 years.
Accelerating Growth: 157's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 157 had negative earnings growth (-64.4%) over the past year, making it difficult to compare to the Personal Products industry average (-8%).
Return on Equity
High ROE: 157's Return on Equity (1.3%) is considered low.
Financial Health
How is Natural Beauty Bio-Technology's financial position?
Financial Position Analysis
Short Term Liabilities: 157's short term assets (HK$400.5M) exceed its short term liabilities (HK$204.7M).
Long Term Liabilities: 157's short term assets (HK$400.5M) exceed its long term liabilities (HK$16.1M).
Debt to Equity History and Analysis
Debt Level: 157's debt to equity ratio (11%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 157's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 157's debt is well covered by operating cash flow (44.6%).
Interest Coverage: 157 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Natural Beauty Bio-Technology current dividend yield, its reliability and sustainability?
0.45%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 157's dividend (0.45%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.12%).
High Dividend: 157's dividend (0.45%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.58%).
Stability and Growth of Payments
Stable Dividend: 157 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are stable.
Growing Dividend: 157 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: 157 is not paying a notable dividend for the Hong Kong market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 157's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.8yrs
Average management tenure
CEO
Yen-Ling Lin (58 yo)
2.75yrs
Tenure
HK$3,119,000
Compensation
Ms. Lin Yen-Ling has been Chief Executive Officer of Natural Beauty Bio-Technology Limited since October 26, 2018. She has been working in Eastern Group since May 2018 as Chief Marketing & Sales Officer of...
CEO Compensation Analysis
Compensation vs Market: Yen-Ling's total compensation ($USD400.94K) is above average for companies of similar size in the Hong Kong market ($USD286.09K).
Compensation vs Earnings: Yen-Ling's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: 157's management team is considered experienced (2.8 years average tenure).
Board Members
Experienced Board: 157's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Natural Beauty Bio-Technology Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Natural Beauty Bio-Technology Limited
- Ticker: 157
- Exchange: SEHK
- Founded: 1972
- Industry: Personal Products
- Sector: Household
- Market Cap: HK$1.341b
- Shares outstanding: 2.00b
- Website: https://www.nblife.com
Number of Employees
Location
- Natural Beauty Bio-Technology Limited
- Hopewell Centre
- Level 54
- Wan Chai
- Hong Kong
Listings
Biography
Natural Beauty Bio-Technology Limited, an investment holding company, manufactures and sells skin care, beauty, aroma-therapeutic, and health supplements and make-up products under the Natural Beauty brand...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/07/29 16:22 |
| End of Day Share Price | 2021/07/29 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.